Baird raised the firm’s price target on Twist Bioscience (TWST) to $48 from $46 and keeps an Outperform rating on the shares. The firm said they reported solid results with performance appearing to be broad-based, with modest revenue upside from each segment versus guidance. Baird continues to be encouraged by the synbio/NGS momentum, commentary around the Express portfolio, and broader GM% improvements and remain constructive on the setup into FY25.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience Reports Record Revenue in 2024
- Twist Bioscience price target lowered to $52 from $55 at Barclays
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Morning Movers: Liberty Energy, Tesla up after President-elect Trump alliance
- Twist Bioscience sees FY25 revenue $367M-$377M, consensus $373.17M